The global vulvovaginal candidiasis treatment market is currently valued at USD 1035 million in 2023 and is anticipated to expand at a CAGR of 4.5%. Owing to the technological advances in healthcare ...

A 2024 nationwide survey of French ICUs reveals critical gaps in managing invasive candidiasis, including underutilization of ...

Scynexis has resumed dosing of its vaginal yeast infection drug Brexafemme (ibrexafungerp) in a Phase III trial after a ...

A month after the FDA lifted its clinical hold on GSK’s vaginal yeast infection drug Brexafemme (ibrexafungerp), the ...

SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial for Brexafemme ...

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

ANTI-INFLAMMATORY The anti-inflammatory properties of cloves result from two essential and powerful phytonutrients, eugenol ...

Resumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and ...

SYDNEY, AUSTRALIA - Media OutReach Newswire - - BioGrowing, a leading Chinese probiotics innovator, marked its debut at the ...

While the science of the gut-vagina connection continues to advance, societal attitudes toward women’s health have not kept pace. In many cultures, vaginal and gastrointestinal symptoms are treated ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...